Objective: To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).
Design: Case report.
Setting: Academic clinical practice and General Clinical Research Center.
Patient(s): A 25-year-old woman with PCOS.
Intervention(s): Rosiglitazone maleate, 4 mg daily for 5 months until conception.
Main outcome measure(s): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.
Result(s): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.
Conclusion(s): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.